III

Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 9, 2022 - 1:00pm
Diamond, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, III, U.S. Securities and Exchange Commission, Association, American Association, Drug discovery, GLOBE, Black Diamond, NEW, R, Private Securities Litigation Reform Act, Investment, Cancer, M26 Modular Accessory Shotgun System, IND, HER2, Annual report, Ishiyama, Glioblastoma, NSCLC, Patient, GBM, Company, Large-cell lung carcinoma, EGFR, II, Program, FGFR, MAP, G&A, BRAF, AACR, Research, American Association for Cancer Research, Nasdaq, Development, Brain, Administration, Food, Investigational New Drug, Pharmaceutical industry, Medical imaging

and NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • and NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
  • Net cash used in operations was $18.1 million for the second quarter of 2022 compared to $25.2 million for the second quarter of 2021.
  • Research and Development Expenses: Research and development (R&D) expenses were $16.2 million for the second quarter of 2022 compared to $26.7 million for the second quarter of 2021.
  • General and Administrative Expenses: General and administrative (G&A) expenses were $7.0 million for the second quarter of 2022, compared to $8.0 million for the second quarter of 2021.

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

Retrieved on: 
Tuesday, August 9, 2022 - 9:30am
HCM, U.S. Securities and Exchange Commission, Psoriasis, Forward-looking statement, GLOBE, Sustainable Stock Exchanges Initiative, CDE, Cancer, Psoriatic arthritis, IND, Hope, Ankylosing spondylitis, Patient, BTK, COVID-19, Center, SAN, Center for Drug Evaluation and Research, HKEX, Therapy, NMPA, Safety, National Medical Products Administration, Protocol, Uveitis, Private Securities Litigation Reform Act, LinkedIn, TEC, AIM, Degenerative disease, Affibody molecule, Pharmacokinetics, III, Pharmaceutical industry, Vaccine

Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022.

Key Points: 
  • Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022.
  • Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis.
  • In addition, IMG-004 and IMG-007, both of which with options on global rights, are in global phase I studies.
  • Inmagene also in-licenses drug candidates and, together with its partners, carries out global development activities, including global multi-center clinical trials.

FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers

Retrieved on: 
Tuesday, August 9, 2022 - 7:18am
FDA, Trial of the century, App, AI, Food and Drug Administration, Classification, Research, SLA, SCIB, Panel, Dermatology, Skin, Skin cancer, Melanoma, MD, US Foods, III, Medical device, Northwestern University

Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more high quality research to validate these technologies.

Key Points: 
  • Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more high quality research to validate these technologies.
  • The Panel underscored the potential risks of reclassifying these technologies and strongly recommended keeping them in the class III category.
  • SciBase shared the same opinion as panel experts through written submissions and oral presentations.
  • SciBase believes the current process where FDA sets very high standards and is closely involved in clinical validation study design is the most appropriate.

Sub-lobar Surgery for Peripheral Non-small Cell Lung Cancer non-inferior to Lobectomy

Retrieved on: 
Monday, August 8, 2022 - 4:00pm
Lung cancer, Survival, Mortality, Neoplasm, Clinical trial, Research, NSCLC, Patient, Lymph, WCLC, Awareness, Lung, International Association, Nominal interest rate, 30 (number), Physician, CI, MD, Conference, III, Alliance, Medical imaging, Silviculture

VIENNA, Aug. 8, 2022 /PRNewswire-PRWeb/ -- A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Key Points: 
  • A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • VIENNA, Aug. 8, 2022 /PRNewswire-PRWeb/ -- A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • In sub-lobar resection, the surgeon removes only the tumor and a small portion of the lung compared to a lobectomy where an entire portion of the lung is removed.
  • The increased detection of small-sized peripheral non-small cell lung cancer has renewed interest in sub-lobar resection in-lieuof lobectomy, according to N.K.

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

Retrieved on: 
Monday, August 8, 2022 - 1:30pm
FDA, III, Prostate cancer, Dean (education), Clinical Genitourinary Cancer, Risk, United Kingdom, Forward-looking statement, GLOBE, ORR, Actinium-225, Private Securities Litigation Reform Act, SEC, Cancer, SPLASH, Medicine, Tulane University School of Medicine, NRG, Laborde, Research, Abiraterone acetate, Patient, NCI, Company, COVID-19, MCRPC, II, NASDAQ, Intention, GU, National Cancer Institute, Oncology, Docetaxel, BC Cancer Agency, MD, RPF, Clinical Science (journal), National, Pharmacokinetics, Terminology, Pharmaceutical industry, Medical imaging, Epidemiology

INDIANAPOLIS, Aug. 08, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, announced that next week, on Thursday, August 18, 2022 at 12:00 PM ET, the Company will be presenting a 45-minute educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”.

Key Points: 
  • He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
  • This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .
  • The forward-looking statements in this press release represent our views as of the date of this press release.

Nautilus, Inc. announces appointment of new board chair, Anne Saunders

Retrieved on: 
Monday, August 8, 2022 - 1:30pm
Home Goods, Health, Retail, Fitness & Nutrition, Specialty, U.S. Securities and Exchange Commission, Multimedia, Exercise, FTD, M.B.A, CEO, NYSE, Audit, Nautilus, Inc., Private Securities Litigation Reform Act, Professional Football Compensation Committee, Starbucks, Security (finance), Annual report, Financial compensation, Habit, Company, COVID-19, Bowflex, Retirement, Form 10-Q, Coffee, Fordham University, Schwinn Bicycle Company, Audit committee, III, Online shopping, Saunders, Nautilus, Northwestern University, Redbox

Nautilus, Inc. (NYSE:NLS), a leader in personalized, connected home fitness, today announced that current board member Anne Saunders has assumed the role of board chair, effective August 2.

Key Points: 
  • Nautilus, Inc. (NYSE:NLS), a leader in personalized, connected home fitness, today announced that current board member Anne Saunders has assumed the role of board chair, effective August 2.
  • View the full release here: https://www.businesswire.com/news/home/20220808005122/en/
    Ms. Saunders appointment to the role was confirmed by the Nautilus board after the Annual Shareholders meeting last Tuesday.
  • In her decade of service to the Nautilus board, Saunders has acted as Chair of the Nominating and Corporate Governance Committee, and as a member of the Audit and Compensation Committees.
  • I am honored to collaborate with the stellar Nautilus team and talented, passionate board that is in place."

Indonesia Data Center Market Investment Analysis & Growth Report 2022-2027: Focus on IT Infrastructure Providers, Construction Contractors, Support Infrastructure Providers, & Data Center Investors

Retrieved on: 
Monday, August 8, 2022 - 12:30pm
Cloud, City, Industry, RESEARCH, WTA Tier III tournaments, Growth, Investment, Communication, Microsoft, Government, 451 Group, Telkomsel, COVID-19, Ministry, AWS, Alibaba Cloud, FTZ 1 TR 6, Ministry of Finance (Indonesia), Digital Park, Telecom, Amazon Web Services, DCI, III, Adoption, Free-trade zone, Renewable energy, Indosat, Informatics, Google

DUBLIN, Aug. 8, 2022 /PRNewswire/ -- The "Indonesia Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 8, 2022 /PRNewswire/ -- The "Indonesia Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Also, the Indonesian data center market is witnessing the entry of new investors, such as Data Center First plans to build data centers in the country.
  • According to the Ministry of Finance Indonesia, the government provides tax incentives to the data center industry to invest in Indonesia.
  • A detailed study of the existing Indonesia data center market landscape, an in-depth industry analysis, and insightful predictions about the Indonesia data center market size during the forecast period.

CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022

Retrieved on: 
Monday, August 8, 2022 - 1:05am
People, Antibody, III, Lung cancer, CSCO, Principal, Survival, Hospital, Risk, RECIST, Carboplatin, OS, Diagnosis, Immunoglobulin G, Cancer, Toxicity, The Lancet, Research, Pemetrexed, NSCLC, Patient, Chemoradiotherapy, Large-cell lung carcinoma, Principal investigator, WCLC, HKEX, Society, Paclitaxel, EGFR, Safety, LBA, ALK, PFS, Conference, Progression-free survival, Disease, Pharmaceutical industry, Engineered wood, Health insurance, Medical imaging, Greater China

Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.

Key Points: 
  • Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.
  • Subgroup analyses demonstrated that sugemalimab was associated with clinical benefits regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.
  • Sugemalimab couldbe safely and effectively used after concurrent or sequential chemoradiotherapy and become a standard of care in this setting for unresectable stage III NSCLC.
  • Subgroup analyses demonstrated that sugemalimab was associated with clinical benefit regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.

CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022

Retrieved on: 
Monday, August 8, 2022 - 1:17am
People, Antibody, III, Lung cancer, CSCO, Principal, Survival, Hospital, Risk, RECIST, Carboplatin, OS, Diagnosis, Immunoglobulin G, Cancer, Toxicity, The Lancet, Research, Pemetrexed, NSCLC, Patient, Chemoradiotherapy, Large-cell lung carcinoma, Principal investigator, WCLC, HKEX, Society, Paclitaxel, EGFR, Safety, LBA, ALK, PFS, Conference, Progression-free survival, Disease, Pharmaceutical industry, Engineered wood, Health insurance, Medical imaging, Greater China

Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.

Key Points: 
  • Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.
  • Subgroup analyses demonstrated that sugemalimab was associated with clinical benefits regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.
  • Sugemalimab couldbe safely and effectively used after concurrent or sequential chemoradiotherapy and become a standard of care in this setting for unresectable stage III NSCLC.
  • Subgroup analyses demonstrated that sugemalimab was associated with clinical benefit regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.

Give Me Back My Youth

Retrieved on: 
Friday, August 5, 2022 - 10:02pm
Breast milk, Gastrointestinal tract, Multimedia, The Non-GMO Project, Mammal, Vitamin, Inflammation, Immunoglobulin G, Tendon, Mineral, Patent, Lactoferrin, Regeneration, Cell, Stomach, Bacteria, Hydroxyproline, Skin, GMP, Ageing, Infection, Organic acid, Colostrum, Virus, Ligament, Collagen, Human, Blood, Proline, Immune system, Health, Muscle, III, Metabolism, Cosmetics, Milk, Tanning (leather)

NASHVILLE, Tenn., Aug. 5, 2022 /PRNewswire/ -- Introducing Give Me Back My Youth, (GMBMY) a one-of-a-kind, patent pending proprietary blend of collagen and colostrum offered by The Root Brands and formulated by Dr. Christina Rahm. Root, an e-commerce, direct to consumer brand, is known for producing the highest quality, natural, bioavailable nutraceuticals and supplements on the market today. Root products help to support the body and strengthen the immune system naturally.

Key Points: 
  • But what if there was a formula to assist the body in bringing back youth?!
  • NASHVILLE, Tenn., Aug. 5, 2022 /PRNewswire/ --Introducing Give Me Back My Youth, (GMBMY) a one-of-a-kind, patent pending proprietary blend of collagen and colostrum offered by The Root Brands and formulated by Dr. Christina Rahm .
  • Formulated to maximize benefits and purity, Give Me Back My Youth has only 2 ingredients: a proprietary, patent pending blend of hydrolyzed bovine collagen and whole colostrum powder.
  • Give Me Back My Youth was developed with the goal to assist in the regenerative support of the cells and the body.